Patent: 10,059,765
✉ Email this page to a colleague
Summary for Patent: 10,059,765
| Title: | Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds |
| Abstract: | The present invention relates, generally, to methods and compositions for increasing the efficiency of therapeutic antibodies. Their efficiency is enhanced through the increase of the ADCC mechanism. More particularly, the invention relates to the use of a therapeutic antibody in combination with compounds that block an inhibitory receptor or stimulate an activating receptor of an NK cell in order to enhance the efficiency of the treatment with therapeutic antibodies in human subjects. |
| Inventor(s): | Velardi; Andrea (Perugia, IT), Romagne; Francois (La Ciotat, FR) |
| Assignee: | INNATE PHARMA S.A. (Marseilles, FR) |
| Application Number: | 14/789,548 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,059,765
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2023-07-24 |
| Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | 05/07/2001 | ⤷ Try a Trial | 2023-07-24 |
| Genzyme Corporation | LEMTRADA | alemtuzumab | Injection | 103948 | 11/14/2014 | ⤷ Try a Trial | 2023-07-24 |
| Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | 10/12/2004 | ⤷ Try a Trial | 2023-07-24 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
